Momentum Builds: Bladder Cancer Trial Data Boost Seagen
- September 22nd, 2023
- 303 views
Astellas Pharma Inc. and Seagen Inc. (Nasdaq: SGEN) have reported promising results from the Phase 3 EV-302 clinical trial (KEYNOTE-A39) for PADCEV (enfortumab vedotin-ejfv) combined with Merck & Co., Inc.'s (NYSE: MRK) KEYTRUDA (pembrolizumab) versus traditional chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC), a severe form of bladder cancer that has spread.
The study achieved its primary endpoints, showing significantly improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Moreover, the combination's safety profile aligns with previously reported findings for the combo enfortumab vedotin - pembrolizumab in cisplatin-ineligible la/mUC patients.
$SGEN was trading at $214.00 in pre-market, up $7.61 (+3.69%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login